Table 4 Crude and adjusted Cox regression models regarding the association of sex steroid treatment with laboratory confirmed SARS-CoV-2 infection or outpatient visits/inpatient hospitalizations with or without the need for ICU admission due to COVID-19
Laboratory confirmed SARS-CoV-2 | Outpatient visits/inpatient hospitalizations with/without ICU admission | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exposed | Unexposed | Exposed | Unexposed | |||||||||
Exposure | Person-time (years) | n events (%) | Person-time (years) | n events (%) | Crude HR (95% CI) | Adjusted HR (95% CI) | Person-time (years) | n events (%) | Person-time (years) | n events (%) | Crude HR (95% CI) | Adjusted HR (95% CI) |
Local estrogens alone | 9346 | 1043 (10.45) | 46,775 | 4552 (9.12) | 1.15 (1.07–1.23) | 1.13 (1.06–1.21) | 9308 | 384 (3.85) | 46,614 | 1523 (3.05) | 1.26 (1.13–1.41) | 1.23 (1.10–1.38) |
Systemic estrogens without progestogens | 3066 | 424 (13.30) | 15,299 | 2211 (13.87) | 0.96 (0.87–1.07) | 0.97 (0.88–1.08) | 3067 | 72 (2.26) | 15,359 | 350 (2.19) | 1.03 (0.80–1.33) | 1.05 (0.82–1.36) |
Estrogens and progestogens | 8237 | 1196 (14.32) | 41,153 | 5615 (13.45) | 1.06 (1.00–1.13) | 1.06 (1.00–1.13) | 8289 | 123 (1.47) | 41,360 | 776 (1.86) | 0.79 (0.66–0.96) | 0.84 (0.69–1.01) |
Progestogens alone | 9148 | 1373 (14.73) | 45,765 | 6601 (14.16) | 1.04 (0.98–1.10) | 1.03 (0.97–1.09) | 9199 | 168 (1.80) | 45,972 | 913 (1.96) | 0.92 (0.78–1.08) | 0.95 (0.81–1.13) |
Tibolone alone | 923 | 144 (15.60) | 4615 | 589 (12.76) | 1.23 (1.02–1.47) | 1.21 (1.01–1.45) | 912 | 23 (2.49) | 4573 | 94 (2.04) | 1.23 (0.78–1.93) | 1.27 (0.80–2.00) |